Phase II Non-Randomized Open Clinical Evaluation of Siddha Medicine “HinguChoornam” for VaayuGunmam (Gastritis)

Shakeena Parveen, A (2021) Phase II Non-Randomized Open Clinical Evaluation of Siddha Medicine “HinguChoornam” for VaayuGunmam (Gastritis). Masters thesis, Government Siddha Medical College, Chennai.

Full text not available from this repository.


An open clinical evaluation of siddha drug Hingu Chooranam in Vaayu Gunmam (Gastritis) was conducted from the year 2018 to 2021 in the Post Graduate Department of Maruthuvam in Govt. Siddha Medical College attached with Arignar Anna Govt. Hospital of Indian Medicine, Chennai. • A total of 40 cases were treated in the Outpatient department. The clinical and Pathological assessment was carried out on the basis of Siddha and Modern aspects. • All the patients were treated with 1 gram of Hingu Chooranam with luke warm water after food twice a day for duration of 30 days. The responses were assessed once in 7 days for all the patients. • The toxicological study revealed no acute and sub acute toxicity in study drug Hingu Chooranam. • The pharmacological study of Hingu Chooranam shows Anti-ulcer activity in Iodoacetamide induced ulcer in Wister rats. • Among 40 patients who participated in the study, 47% were male and 53% were female. There is no significant difference found based on gender. • The peak incidence of Vaayu Gunmam was found in 41 to 50 years age group (47.50%). • The disease is more common in home makers (30%). • It is seen that people from lower middle (52.50%) income category has higher incidence of gastritis. • Regarding diet, the disease is more common among mixed diet category (87.50%). • Regarding personal habits 10% were smokers, 17.50% were alcoholics, 10% were both smokers & alcoholics and 62.50% does not have any such habits. • Chronicity of illness showed that most of them suffered from this illness for duration of 1 to 3 years (40%). • Among 40 patients 15% were having positive family history and 85% does not have any positive family history related to Vaayu Gunmam. • Regarding Thinai, most of the patients were from Neithal nilam (77.50%) • In accordance with Kaalam, most of the patients belong to Pitha Kaalam (77.50%). • In respect to Paruva Kaalam, 50% of patients reported in Koothir Kaalam and 50% of patients reported in Munpani Kaalam. • The disease is more common in Vatha yakkai patients (42.50%). • In Vatham Before treatment Piraanan (67.50%), Abaanan (57.50%), Viyaanan (87.50%), Udhaanan (77.50%), Samaanan (100%), Kirukaran (70%) were affected. After the treatment with study drug 95% improvement seen in Piraanan, 100% improvement seen in Abaanan, 90% improvement seen in Viyaanan, 88% improvement seen in Udhaanan, 88% improvement seen in Samaanan, 95% improvement seen in Kirukaran respectively. • In Pitham Before treatment Anar Pitham (75%), Ranjaga Pitham (20%), Saadhaga Pitham (100%) were affected. After the treatment with study drug 90% improvement seen in Anar Pitham, 95% improvement seen in Ranjaga Pitham, 90% improvement seen in Saadhaga Pitham respectively. • In Kabam Before treatment Avalambagam (100%), Kilethagam (80%), Pothagam (10%) and Santhigam (15%) were affected. After treatment 83% improvent seen in Avalambagam, 90% improvement seen in Kilethagam,100% improvement seen in Pothagam and 93% improvement seen in Santhigam respectively. • In Ezhu Udal Thathukkal, Before treatment Saaram (100%), Senneer (20%), Kozhuppu (15%), Enbu (15%) were affected. After the treatment with study drug 88% improvement seen in Saaram, 90% improvement seen in Senneer, 93% improvement seen in Kozhuppu, 95% improvement seen in Enbu respectively. • In Envagai Thervugal Naa (20%), Malam (57.5%) were affected. After the treatment with study drug 90% improvement seen in Naa, 100%, improvement seen in Malam respectively. • Regarding Naadi, Before treatment 47.50% had Vatha Pitha Naadi and 30% had Pitha Vatha Naadi, 5% had Kaba Vatha Naadi and 17.50% had Kaba Pitha Naadi. After treatment 32.50% had Vatha Pitha Naadi and 40% had Pitha Vatha Naadi, 2.50% had Kaba Vatha Naadi and 25% had Kaba Pitha Naadi. • Regarding Neikuri, Before treatment 10% had Vatha Neikuri, 17.50% had Pitha Neikuri, 12.50% had Kaba Neikuri,40% had Vatha Pitha Neikuri, 20% had Pitha Vatha Neikuri. After treatment, 10% had Vatha Neikuri, 27.50% had Pitha Neikuri, 22.50% had Kaba Neikuri, 50% had Vatha Pitha Neikuri, 12.50% had Pitha Vatha Neikuri. • Assessment of clinical features revealed that Before Treatment Indigestion was present in 77.50%, Nausea in 37.50%, Vomiting in 7.50%, Abdominal bloating in 97.50%, Generalized weakness in 10%, Lower abdominal pain in 77.50%. After treatment, 75% improvement seen in Indigestion, 95% improvement seen in Nausea,100% improvement seen in Vomiting, 70% improvement seen in Abdominal bloating, 100% improvement seen in Generalized weakness, 75% improvement seen in Lower abdominal pain. Since the p – value of most of the clinical features are significant, it shows good improvement after the administration of the drug. • Statistical analysis of Gastrointestinal Symptoms Rating Scale (GSRS scale) shows that the p value for most of the gastrointestinal symptoms were found to be < 0.05 which means there is significant improvement in most of the patients after treatment. Hence null hypothesis is rejected. It shows that the trial medicine Hingu Chooranam is effective for Vaayu Gunmam. • From the results of statistical analysis of routine blood investigations, it is seen that the p value of parameters like Total cell count & Differential count was found to be <0.05, hence we can reject the null hypothesis. But in other parameters like ESR, Haemoglobin & Blood sugar, since the p value is >0.05 null hypothesis is accepted. • In specific investigations, among 40 patients, 8 patients undergone endoscopic evaluation before treatment and their results revealed presence of Gastritis. In Rapid Urease test, among 40 patients 4 patients undertook this test and 3 of them were found to be positive for H.pylori. • The outcome of the study reveals that among 40 participants, 67.50% had good improvement, 20% had moderate improvement and 12.50% had mild improvement. CONCLUSION: Vaayu Gunmam (Gastritis) is mainly caused due to derangement of uyir thathu - Vatham (Piraanan, Abaanan, Viyaanan, Udhaanan, Samaanan, Kirukaran) along with Pitham (Anar Pitham, Ranjaga Pitham, Saadhaga Pitham). The ingredients present in the Hingu Chooranam have Kaarppu, Kaippu, Thuvarppu Suvai thus it countervailed the deranged uyir thathukal and provided ease for all the patients with Vaayu Gunmam. Also the trial medicine showed good symptomatic improvement in patients with Helicobacter pylori infection. The preclinical studies revealed no acute and sub acute toxicity which proves that Hingu Chooranam is safe for human administration. Further the pharmacological study shows that the trial drug Hingu Chooranam possess significant anti -ulcer potential. No adverse effects of the trial drug were reported during the course of the study. As the study drug is palatable and cost effective it can be utilized for huge population in public health sector. Based on all the pre-clinical and clinical evidences, the author concludes that the trial medicine Hingu Chooranam is one of the best choice for treating Vaayu Gunmam (Gastritis). Further there is a scope for research on this trial drug if it is done on larger sample size with longer duration for the benefit of the society.

Item Type: Thesis (Masters)
Additional Information: 321811108
Uncontrolled Keywords: Siddha Medicine, Hingu Choornam, Vaayu Gunmam, Gastritis, Phase II Non-Randomized Open Clinical Evaluation.
Subjects: AYUSH > Maruthuvam
Depositing User: Subramani R
Date Deposited: 17 Nov 2022 13:43
Last Modified: 17 Nov 2022 13:43

Actions (login required)

View Item View Item